Showing results (71-80 of 128) with videos related to
Sort By:
Pageof 13
Cancer Immunity|October 29, 2003
Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccineDanila Valmori, Valérie Dutoit, Maha Ayyoub, et al.The Journal of Biological Chemistry|May 3, 2012
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsivenessMelita Irving, Vincent Zoete, Michael Hebeisen, et al.Cancer Immunology, Immunotherapy : CII|September 30, 2006
Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitroJinfei Chen, Anita Schmitt, Baoan Chen, et al.Cancer Research|December 30, 2011
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1Julien Fourcade, Zhaojun Sun, Ornella Pagliano, et al.The Journal of Biological Chemistry|April 5, 2005
CD8+ cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimersMarek Cebecauer, Philippe Guillaume, Silke Mark, et al.Experimental Hematology|July 16, 2008
Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigensFei Fei, Yingzhe Yu, Anita Schmitt, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2007
Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cellsRalf-Holger Voss, Ralph A Willemsen, Jürgen Kuball, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cellsMikaël J Pittet, Verena Rubio-Godoy, Gilles Bioley, et al.The Journal of Biological Chemistry|June 27, 2008
Increased mobility of major histocompatibility complex I-peptide complexes decreases the sensitivity of antigen recognitionJean-Manuel Segura, Philippe Guillaume, Silke Mark, et al.Journal for Immunotherapy of Cancer|May 26, 2020
Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patientsGeorg Alexander Rockinger, Philippe Guillaume, Amélie Cachot, et al.Pageof 13